Ranbaxy Mohali Plant's U.S. Acceptance May Have Hung By A Hair
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA's ban on drugs imported from the Mohali, India, production plant of Ranbaxy Laboratories appears to have been based in part on detection of a possible arm hair embedded in a single tablet.